Skip to main content
Clinical Trials/CTRI/2019/08/020855
CTRI/2019/08/020855
Completed
Phase 2

Clinical evaluation of the effect on oral administration of PAÃ?CA CŪTA MEḺUKU along with external POṬI TIMIRTAL therapy in management of MÄ?L MŪCCU VÄ?TAM

Geetha Sudheer R0 sites7 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Health Condition 1: G710- Muscular dystrophy
Sponsor
Geetha Sudheer R
Enrollment
7
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
June 23, 2020
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Geetha Sudheer R

Eligibility Criteria

Inclusion Criteria

  • Subject should be positive for at least two of the criteria given below
  • 1\. Elevated CPK levels
  • 2\. Genetic testing: Pathogenic deletion, duplication or point mutation of muscular dystrophy related genes
  • 3\. Gait abnormality: waddling, wide\-based gait with hyperlordosis of the lumbar spine and toe walking
  • 4\. Positive Gowerâ??s sign
  • 5\. Phenotypic evidence of muscular dystrophy
  • Willing for functional assessment and ability to comply with scheduled visits, and study restrictions.

Exclusion Criteria

  • Children with
  • Heart failure
  • Continuous mechanical ventilation
  • Under continuous usage of other medications
  • Renal insufficiency, retinal disorder,
  • Hypotension or Hypertension

Outcomes

Primary Outcomes

Not specified

Similar Trials